Altif Laboratories

Tokyo Metropolitan Institute of Medical Science

Tokyo Metropolitan Organization for Medical Research

Jcr Pharmaceuticals Co., Ltd.

Youichi Tajima

Shinji Takeoka

Atsushi Mizuno

Hitoshi Sakuraba

Seiichi Aikawa

Fumiko Aikawa

Mai Ito

Ikuo Kawashima

Katsuji Ohta

Manabu Ito

The present invention provides a pharmaceutical composition comprising a protein having &#x3b1;-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an &#x3b1;-galactosidase activity through alteration of the structure of the active site of wild-type human &#x3b1;-N-acetylgalactosaminidase.

Polynucleotides encoding proteins having acquired &#x3b1;-galactosidase activity

The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having &#x3b1;-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired &#x3b1;-galactosidase activity by changing the structure of the active site of wild-type human &#x3b1;-N-acetylgalactosaminidase.

Highly functional enzyme having alpha-galactosidase activity

Highly functional enzyme having &#x3b1;-galactosidase activity

Proteins having acquired A-galactosidase activity

Growing community of inventors

Tokyo, Japan

Youichi Tajima